MyMD Pharmaceuticals Inc. (NASDAQ:MYMD) shares traded 31.82% higher at $1.45 on Wall Street last session.
In accordance with the data, 1 analysts cover MyMD Pharmaceuticals Inc. (NASDAQ:MYMD). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $1536.00 and a low of $1536.00, we find $1536.00. Given the previous closing price of $1.10, this indicates a potential upside of 139536.36 percent. MYMD stock price is now -3.90% away from the 50-day moving average and -19.07% away from the 200-day moving average. The market capitalization of the company currently stands at $58.13M.
It has been rated a hold by 0 analysts and a buy by 1. Brokers who have rated the stock have averaged $1536.00 as their price target over the next twelve months.
In other news, Rivard Paul, EVP of Operations, GC bought 10,000 shares of the company’s stock on Dec 08. The stock was bought for $15,300 at an average price of $1.53. Upon completion of the transaction, the EVP of Operations, GC now directly owns 225,000 shares in the company, valued at $0.33 million. A total of 0.60% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in MYMD stock. A new stake in MyMD Pharmaceuticals Inc. shares was purchased by PARALLEL ADVISORS, LLC during the first quarter worth $36,000. NWAM LLC invested $36,000 in shares of MYMD during the first quarter. In the first quarter, COMMONWEALTH EQUITY SERVICES, LLC acquired a new stake in MyMD Pharmaceuticals Inc. valued at approximately $25,000. CI PRIVATE WEALTH, LLC acquired a new stake in MYMD for approximately $22,000. KESTRA PRIVATE WEALTH SERVICES, LLC purchased a new stake in MYMD valued at around $18,000 in the second quarter.
MyMD Pharmaceuticals Inc. (NASDAQ: MYMD) opened at $1.3500 on Monday. During the past 12 months, MyMD Pharmaceuticals Inc. has had a low of $0.80 and a high of $6.15. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 10.00, and a quick ratio of 10.00. The fifty day moving average price for MYMD is $1.4972 and a two-hundred day moving average price translates $1.7869 for the stock.
The latest earnings results from MyMD Pharmaceuticals Inc. (NASDAQ: MYMD) was released for Mar, 2023.
MyMD Pharmaceuticals Inc.(MYMD) Company Profile
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
